This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E70.3 (Cross syndrome; same code as albinism and Chediak-Higashi, but a separate file) | OMIM: 257800 | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Cross syndrome, Cross-McKusick-Breen syndrome, Oculocerebral syndrome with hypopigmentation (OCS-H), OMIM #257800 |
| C. Adult onset | Likelihood of first presentation in adulthood none (severe congenital disease) — skin and hair pigment deficiency and severe ocular abnormalities are evident from birth, and the disease is already diagnosed in infancy to childhood because of severe neurodevelopmental delay and physical growth failure. Most patients die early. |
| 1. History | Cross HE, McKusick VA and Breen W first described a combined syndrome of hypopigmentation, microphthalmia, intellectual disability and nystagmus in 1967 → registered as OMIM #257800 → sporadic reports of extremely rare cases continue with the causative gene unidentified → presumed autosomal recessive inheritance. |
| 2. Causes | Causative gene unidentified (as of 2025). Presumed: possibly a defect in a gene commonly involved in nervous system development together with abnormal melanocyte development or pigment migration. Occurrence in consanguineous families → strongly suggests autosomal recessive. Some authors: candidate genes such as TYRP1 or VPS33A proposed. |
| 3. Genetics | Presumed autosomal recessive. Reports of affected siblings of consanguineous parents strongly support autosomal recessive inheritance. Molecular diagnosis impossible because the causative gene is unidentified. OMIM #257800. Recent attempts to identify the causative gene by whole-exome sequencing (WES) are under way. |
| 4. General epidemiology | Fewer than 20–30 cases reported worldwide. Incidence unknown (estimated <1:1,000,000). No or very few reports from Korea and Asia. More frequent in consanguineous populations. Males and females equal. |
| 5. Pathophysiology | Dual pathology of pigment deficiency + abnormal central nervous system development. Defects in melanocyte development and migration cause absence of pigment in the skin, iris and retina. Defects in neurodevelopmental genes cause abnormal brain development (cerebellar atrophy, cerebral cortical abnormalities, lowered seizure threshold). Defects in eye formation (microphthalmia, corneal opacity) possibly due to abnormalities in eye development genes. Mechanism of gingival fibromatosis unclear. |
| 6. Symptoms | Skin and hair hypopigmentation (silvery white to light blond). Microphthalmia. Corneal clouding. Nystagmus. Spastic quadriplegia. Intellectual disability (severe). Growth failure (short stature, low weight). Gingival fibromatosis. Ectropion. |
| 7. Signs | White or silvery white hair. Microphthalmia (clinical measurement). Corneal opacity (slit lamp). Spastic limbs (neurologic examination). Brain MRI: cerebellar atrophy, cerebral abnormalities. Gingival hypertrophy and fibromas (oral examination). Indicators of growth delay. Nystagmus (ophthalmologic examination). |
| 8. Screening | Not covered by newborn screening. Clinical suspicion from examination at birth (skin hypopigmentation + microphthalmia + corneal opacity) is the only means of early detection. Check family history (consanguineous marriage, affected siblings). Immediate referral to ophthalmology and neurology. |
| 9. Diagnosis | Clinical diagnosis (5 key features: hypopigmentation + microphthalmia + corneal opacity + nystagmus + intellectual disability). Ophthalmologic examination (microphthalmia measurement, corneal slit lamp, fundus). Brain MRI (cerebral and cerebellar abnormalities). Skin biopsy (reduced melanocytes). Whole-exome sequencing (WES) or clinical exome sequencing — search for causative gene. Hereditary albinism gene panel (for differentiation from OCA/OA). |
| 10. Treatment | No curative treatment — mainly symptom management. Seizures: anticonvulsants (valproic acid, levetiracetam, etc.). Muscle spasticity: baclofen, physical therapy, assistive devices. Ophthalmology: consider corneal transplantation for corneal opacity (limited effect on visual recovery). Nutrition: tube feeding (for dysphagia). Gingival fibromatosis: periodontal surgery. Multidisciplinary rehabilitation (physical therapy, occupational therapy, speech therapy). |
| 11. Prognosis | Prognosis very poor. Severe neurologic damage (spastic quadriplegia, severe intellectual disability) is permanent and progressive. Many reported patients died within childhood. Surviving patients are completely dependent because of severe disability. Risk of death from opportunistic infections such as pneumonia and urinary tract infection. |
| 12. Prevention | Primary: advice to avoid consanguineous marriage, genetic counseling. Prenatal genetic diagnosis impossible until the causative gene is identified. Prenatal diagnosis possible once the causative gene is identified. Secondary: immediate multidisciplinary supportive treatment after early clinical detection. Tertiary: management of seizure, infection and nutritional complications, psychological support and caregiving support for the family. |
| 13. References | Cross HE, McKusick VA, Breen W. A new oculocerebral syndrome with hypopigmentation. J Pediatr. 1967. and 9 other papers |
Cross syndrome is an extremely rare hereditary disease first described in 1967 in a paper published in the Journal of Pediatrics by the American ophthalmologist Harold E. Cross, the medical geneticist Victor A. McKusick and William Breen (PMID: 4959856). They reported cases of children from the Amish community, including two sets of siblings, with a combined clinical picture of marked pigment deficiency of the skin and hair, microphthalmia, corneal opacity, nystagmus, gingival fibromatosis, severe intellectual disability and spastic quadriplegia.
In this paper, the authors argued that these cases were a new clinical syndrome that matched no previously described disease and named it "A new oculocerebral syndrome with hypopigmentation". The syndrome later became known, after the three reporters, as Cross-McKusick-Breen syndrome or Cross syndrome. It is registered in OMIM as #257800.
In the decades after the first report, similar cases were reported sporadically around the world, but the spectrum of clinical features differed somewhat from report to report. Some reports described cases without gingival fibromatosis or occurrence in families unrelated to consanguineous marriage. This led to ongoing debate over whether "Cross syndrome" is a single-gene disease or a collection of clinical syndromes caused by several different gene defects with similar phenotypes.
As of 2025, the causative gene has not been clearly identified. In early reports, the observation of affected siblings in small populations where consanguineous marriage is common, such as the Amish community, strongly suggested autosomal recessive inheritance. Most cases reported worldwide since then have also had a family background of consanguineous marriage or affected siblings, so autosomal recessive inheritance is the current official position.
Recently, with advances in next-generation sequencing (NGS), especially whole exome sequencing (WES), attempts are being made to identify the causative gene in patients with suspected Cross syndrome, and some candidate genes have been proposed. However, no causative gene validated on a large scale has yet been established, so clinical diagnosis still relies on the combination of clinical symptoms and diagnosis of exclusion. Identifying the molecular cause of this disease also has important implications for differentiation from similar syndromes (Angelman syndrome, Hermansky-Pudlak, Chediak-Higashi, etc.).
As of 2025, the molecular cause of Cross syndrome has not been established. However, taken together, the clinical and epidemiological data suggest that the cause is loss-of-function variants in genes commonly required for the pathways involved in melanocyte development and pigment formation and for central nervous system development.
The occurrence of affected siblings in consanguineous families and reports of cases in which only one of dizygotic twins was affected strongly support autosomal recessive inheritance. Homozygous or compound heterozygous pathogenic variants in an autosomal recessive gene are likely to be the cause. Clustering in the Amish founder population suggests accumulation of a specific founder variant.
Regarding candidate causative genes, some researchers have proposed the TYRP1 (tyrosinase-related protein 1) gene or the VPS33A (vacuolar protein sorting 33A) gene as candidates. VPS33A is a protein involved in the sorting and fusion of intracellular organelles, and there is a theoretical basis for its deficiency affecting not only melanosome function but also nerve cell function. However, these candidate genes have not been established as universal causes of Cross syndrome, and clinical heterogeneity between cases is not fully explained by a single-gene mechanism.
In addition, some reported suspected cases of Cross syndrome are difficult to clearly distinguish from other known syndromes (e.g., rare variants of Hermansky-Pudlak syndrome, atypical phenotypes of Angelman syndrome, atypical Chediak-Higashi), so some patients with Cross syndrome may be reclassified as having other diseases through future molecular diagnosis. This is a diagnostic uncertainty that clinicians dealing with this syndrome must recognize.
Because the molecular cause has not been identified to date, genetic testing for confirmation is not standardized in clinical practice. In suspected patients, a search for the causative gene by whole-exome sequencing (WES) or whole-genome sequencing (WGS) is recommended.
There is current consensus that Cross syndrome follows presumed autosomal recessive inheritance. It is registered as OMIM #257800 and is marked with the "%" symbol, indicating that its molecular basis has not yet been established.
The evidence for autosomal recessive inheritance is as follows. First, in the first report in 1967, several siblings were affected in an Amish family with consanguineous (first-cousin) marriage. Second, consanguineous parents or affected siblings were identified in many subsequently reported cases. Third, the parents were clinically unaffected, suggesting recessive inheritance. These three lines of evidence strongly support autosomal recessive inheritance.
Because the causative gene has not been established, molecular genetic carrier testing or prenatal DNA diagnosis cannot currently be performed as standard. However, in families with affected siblings in whom a candidate causative variant has been identified by WES or WGS, targeted prenatal diagnosis using that variant is theoretically possible.
Genetic heterogeneity of Cross syndrome must also be considered. The variation among reported cases in the presence of gingival fibromatosis, the severity of neurologic symptoms and the degree of ocular abnormalities suggests the possibility of heterogeneity that a single gene variant cannot explain. Therefore, patients with actually different gene defects may be included under the single diagnostic name "Cross syndrome".
In genetic counseling, it must be clearly explained to parents that the causative gene has not been identified to date. Under the assumption of autosomal recessive inheritance, the recurrence risk in the next pregnancy of parents with an affected child is 25%. Avoiding consanguineous marriage is the only realistic preventive measure against further cases. Specific genetic counseling and prenatal diagnosis are possible only when a candidate causative variant has been identified by WES or WGS.
Cross syndrome is an extremely rare disease with fewer than 20–30 cases reported worldwide. The exact incidence is unknown, and the estimated incidence is 1:1,000,000 or less. From the first report in 1967 through the 2020s, only about 20–25 cases have been described in the literature.
In terms of geographic distribution, the first cluster was reported in the Amish population of the United States, and sporadic cases were subsequently reported from the Middle East (Iran, Jordan, United Arab Emirates), Turkey, Pakistan, India, Europe and elsewhere. The pattern of occurrence mainly in populations where consanguineous marriage is relatively common (Middle East, parts of South Asia, Amish, etc.) is consistent with autosomal recessive inheritance. There are no or very few reported cases in East Asia, including Korea.
The sex distribution is equal between males and females. Because inheritance is autosomal recessive, there is no difference in frequency by sex. Because the causative gene is unidentified, the actual prevalence may be underreported. That is, when clinical symptoms are atypical or misdiagnosed as other diseases (Chediak-Higashi, Hermansky-Pudlak, etc.), cases may not be classified as Cross syndrome.
Because the incidence is extremely low, there are almost no specialized medical institutions with accumulated clinical experience, and treatment experience and natural history data are very scarce. Establishing international case registration and data-sharing systems is needed to obtain accurate epidemiological data on this disease.
In terms of rare disease classification, Cross syndrome is included in the Korean rare disease list, is classified under ICD-10 code E70.3 and is covered by Special Copayment Reduction V117. However, the number of patients in Korea is not known.
Because the causative gene of Cross syndrome has not yet been identified, its pathophysiology relies on inference based on pathologic observations. The dual pathology of pigment deficiency and central nervous system abnormalities seen clinically suggests a defect in a gene or pathway commonly involved in pigment formation and nervous system development.
Mechanism of pigment deficiency: cases have been reported in which skin biopsy showed reduced or nonfunctional melanocytes. This suggests a defect in melanocyte migration from the neural crest or abnormal melanosome function (a mechanism different from conventional OCA or OA). Melanocytes of the iris, retinal pigment epithelium, skin and hair follicles all show pigment deficiency, and the appearance is similar to OCA1A, but the molecular mechanism is presumed to be different.
Abnormal eye formation: microphthalmia indicates a defect in eye development itself, beyond simple pigment deficiency. Corneal opacity also reflects abnormal corneal development. This suggests that Cross syndrome is not simply a defect of pigment-forming enzymes but includes abnormalities of pathways involved in eye development itself. This is the key feature that distinguishes it from simple OCA.
Abnormal central nervous system development: brain MRI shows cerebellar hypoplasia, cerebral cortical dysplasia, ventricular enlargement and other findings. Spastic quadriplegia reflects damage to cortical or subcortical pathways, and severe intellectual disability indicates global abnormal brain development. These nervous system abnormalities are congenital (arising before birth), presumably caused by defects in genes involved in nervous system development during fetal development.
Gingival fibromatosis: caused by proliferation of gingival connective tissue; its pathologic relationship to pigment deficiency and neurologic abnormalities is not yet clear. Abnormalities of connective tissue matrix proteins or growth factor signaling are presumed to be the cause.
The clinical symptoms of Cross syndrome consist of combined abnormalities of the pigmentary system, eyes, nervous system and mouth. The main reported clinical features are listed below.
Pigment deficiency: pigment of the skin and hair is markedly reduced or absent, resembling albinism. The hair is silvery white to light blond, and the skin is very white. This is clinically similar to OCA1A, but the molecular cause is different. Iris pigment is also reduced and may become light blue-gray or pink.
Ocular abnormalities: microphthalmia is the most characteristic ocular finding and occurs unilaterally or bilaterally. Corneal clouding accompanies it, and reduced vision is marked. Nystagmus appears in most patients. Ectropion has also been reported. Unlike the ocular abnormalities of OCA, which are due simply to absent pigment, these ocular abnormalities include structural developmental defects and are therefore more severe.
Neurologic abnormalities: severe intellectual disability appears in all reported cases, and development of independent functional communication is very limited. Spastic quadriplegia or spastic diplegia appears, and seizures may accompany it. A transition from hypotonia to hypertonia is sometimes observed.
Growth disorder: short stature and low weight are marked, and feeding difficulties contribute to growth delay.
Oral abnormalities: gingival fibromatosis is characteristic but does not necessarily appear in all reported cases. The gums may gradually thicken and cover the teeth.
The objective signs of Cross syndrome are confirmed by clinical examination, ophthalmologic examination and brain imaging.
Pigment deficiency: visible depigmentation of the skin and hair (silvery white hair, pale skin). Light blue-gray or pink discoloration of the iris. Iris transillumination possible on slit lamp.
Microphthalmia: eye measurement shows ocular diameter reduced below the normal range. Bilateral or unilateral. Ocular dysfunction accompanies the reduced eye size.
Corneal opacity: varying degrees of corneal opacity on slit lamp examination. A direct cause of reduced vision.
Neurologic signs: signs of upper motor neuron lesions such as bilateral deep tendon hyperreflexia, positive Babinski sign and clonus. Increased tone of spastic limbs (spasticity). Marked delay in developmental milestones.
Brain MRI abnormalities: cerebellar hypoplasia or atrophy, cerebral cortical dysplasia, ventricular enlargement, white matter abnormalities and others are reported.
Gingival hypertrophy: thickening or fibromatous proliferation of the gums on oral examination. Delayed tooth eruption or impacted teeth.
Indicators of growth delay: height, weight and head circumference persistently in the lower percentiles for age.
Cross syndrome is not a target of standard newborn screening (DBS MS/MS), because no metabolite abnormalities or specific biochemical biomarkers have been identified. Early detection therefore depends on clinical examination immediately after birth.
Early detection by clinical examination: if the following combination is observed simultaneously in a newborn or infant, differential diagnosis including Cross syndrome should be started immediately: ① marked pigment deficiency of the skin and hair (albinism pattern), ② microphthalmia, ③ corneal opacity, ④ nystagmus. This clinical combination is an important clue distinguishing it from simple OCA.
Family history assessment: always check whether the parents are consanguineous and whether there are affected siblings. When there is consanguineous marriage and an affected sibling, the likelihood of an autosomal recessive rare disease rises greatly.
Immediate ophthalmology and neurology referral: suspected cases are referred immediately to an ophthalmologist (evaluation of microphthalmia and cornea) and a pediatric neurologist (evaluation of neurodevelopmental abnormalities). Neurologic evaluation including brain MRI should be done quickly.
Diagnosis of exclusion: Chediak-Higashi syndrome (giant granules on peripheral blood smear), Hermansky-Pudlak syndrome (platelet function tests), Angelman syndrome (methylation analysis) and atypical OCA (genetic testing of TYR/OCA2/SLC45A2, etc.) must be systematically excluded. If the diagnosis remains unclear after these are excluded, WES or WGS is recommended.
Because there is no specific molecular test, confirmation of Cross syndrome depends on clinical criteria and diagnosis of exclusion.
Clinical diagnostic criteria (coexistence of 5 key features): ① hypopigmentation or depigmentation of the skin, hair and iris, ② microphthalmia, ③ corneal opacity, ④ nystagmus, ⑤ severe intellectual disability and spastic paralysis. When these five coexist, Cross syndrome is strongly suggested. Gingival fibromatosis is characteristic but does not necessarily appear in every case.
Ophthalmologic examination: slit lamp (corneal opacity, iris pigment, transillumination), fundoscopy (state of retinal pigment epithelium), eye measurement (confirmation of microphthalmia). Visual evoked potentials (VEP).
Brain MRI: confirm the pattern of abnormal brain development, including cerebellar, cerebral and white matter abnormalities, ventricular size and development of the corpus callosum.
Skin biopsy (optional): evaluation of melanocyte number and morphology. Confirmation of melanosome abnormalities by electron microscopy.
Exclusion tests: peripheral blood smear (checking for giant granules to exclude Chediak-Higashi). Platelet aggregation test (to exclude Hermansky-Pudlak). 15q11-q13 methylation analysis (to exclude Angelman syndrome). OCA gene panel (to exclude TYR, OCA2, TYRP1, SLC45A2).
Whole-exome sequencing (WES): when Cross syndrome is strongly suspected after diagnosis of exclusion, WES is performed to search for the causative gene and for future family counseling. Concurrent WES of the parents (trio WES) is advantageous for identifying the causative variant.
There is no curative treatment for Cross syndrome, and all current treatment is multidisciplinary conservative care aimed at symptom relief, prevention of complications and support of quality of life.
Neurologic treatment: for seizure control, anticonvulsants (valproic acid, levetiracetam, clonazepam, etc.) are used according to the cause. Drugs are chosen according to seizure type (generalized, partial) and EEG characteristics. For spasticity, baclofen (oral or intrathecal infusion), tizanidine and botulinum toxin injection (at sites of focal spasticity) are used.
Ophthalmologic treatment: corneal transplantation (penetrating keratoplasty or DALK) may be considered for reduced vision due to corneal opacity, but surgical results are limited when microphthalmia is present. Corrective lenses for refractive errors (when possible). Prism glasses for nystagmus. Tinted lenses to relieve photophobia.
Nutritional support: for dysphagia, tube feeding through a nasogastric tube (NG tube) or percutaneous endoscopic gastrostomy (PEG). Collaboration with a dietitian and a swallowing therapist.
Oral treatment: for gingival fibromatosis, hypertrophied gum tissue is removed by periodontal surgery (gingivectomy, gingivoplasty). Recurrence is common, so repeated surgery may be needed.
Rehabilitation: physical therapy (relieving spasticity, maintaining range of motion, supporting mobility), occupational therapy (maximizing daily function), speech therapy (communication support, dietary adjustment). Provision of a special education environment suited to severe intellectual disability.
Skin protection: because pigment deficiency makes the skin vulnerable to ultraviolet light, sunscreen and protective clothing are needed (management equivalent to albinism).
The prognosis of Cross syndrome is very poor. Because of the combination of severe neurologic damage and multiorgan abnormalities, severe disability persists in most patients.
In reported cases, some patients died within childhood, and the causes of death were mainly opportunistic infections and complications such as recurrent pneumonia, aspiration pneumonia, urinary tract infection and malnutrition. With severe dysphagia, the risk of aspiration pneumonia is very high.
In surviving patients, intellectual disability and spastic quadriplegia are permanent and do not improve. Vision is functionally very limited because of microphthalmia and corneal opacity, and independent mobility or communication is almost impossible. Life completely dependent on care is unavoidable.
Even among long-term survivors, reports of survival into adulthood are very rare. Patients who reach adulthood need ongoing medical support and support for fully dependent daily living. To date, there is insufficient evidence that therapeutic interventions have meaningfully improved long-term survival or quality of life.
The severe natural course of this disease, its poor prognosis and the current absence of curative treatment should be conveyed to the family clearly and empathetically, and early linkage to a palliative care approach and family support services is important.
Because the causative gene of Cross syndrome has not been identified, fundamental genetic prevention is limited. Realistic prevention is carried out as follows.
Primary prevention: the most effective primary prevention is avoiding consanguineous marriage. Families in which Cross syndrome has occurred, especially those with a background of consanguineous marriage, should be informed of the risks of consanguineous marriage through genetic counseling. While the causative gene remains unidentified, standard carrier testing or prenatal DNA diagnosis is impossible. In families in whom a candidate causative variant has been identified by WES, targeted prenatal genetic diagnosis is possible.
Secondary prevention (early detection): it is important to recognize immediately, on clinical examination right after birth, the combined findings suggesting Cross syndrome (hypopigmentation + microphthalmia + corneal opacity) and to start multidisciplinary evaluation and supportive treatment promptly. Early intervention may partially delay complications or partially support quality of life.
Tertiary prevention (minimizing complications): early seizure control (appropriate anticonvulsants), prevention of aspiration pneumonia (tube feeding, positioning), prevention of malnutrition, skin protection (UV protection), oral hygiene and management of gingival fibromatosis. Emotional support for the family and linkage to social welfare resources to reduce the caregiving burden are essential.